Dopamine receptor: Difference between revisions
imported>Robert Badgett (New page: Dopamine receptors are "cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells."<ref name="MeSH-DopamineRecepto...) |
imported>Meg Taylor (subpages) |
||
| Line 1: | Line 1: | ||
{{subpages}} | |||
[[Dopamine]] receptors are "cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells."<ref name="MeSH-DopamineReceptors">{{MeSH|Receptors, Dopamine}}</ref> | [[Dopamine]] receptors are "cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells."<ref name="MeSH-DopamineReceptors">{{MeSH|Receptors, Dopamine}}</ref> | ||
Latest revision as of 06:50, 30 September 2009
Dopamine receptors are "cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells."[1]
Classification
D1-like receptors
These receptors stimulate adenylate cyclase.[2]
D1 receptors
D5 receptors
D2-like receptors
These receptors inhibit adenylate cyclase.[3]
Dopamine D2 receptors
Agonists, such as metoclopramide, are used as antiemetics.
Antagonists, such as risperidone and haloperidol, are used to treat schizophrenia.[4]
Blockade of the D2 receptors, which may be predisposed by genetic polymorphisms of the allele, may cause neuroleptic malignant syndrome.[5]
D3 receptors
Agonists of D3, especially nonergot agonists such as pramipexole and ropinirole, may be used to treat Parkinonism and restless legs syndrome.[6]
D4 receptors
Novelty seeing personality trait may be related to polymorphisms in the dopamine receptor D4 that affects dopamine activity in the tuberoinfundibular dopaminergic system.[7]
References
- ↑ Anonymous (2024), Receptors, Dopamine (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Receptors, Dopamine D1 (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Receptors, Dopamine D2 (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Katzung, Bertram G. (2001). Basic & clinical pharmacology. New York: Lange Medical Books/McGraw-Hill, 483. ISBN 0-8385-0598-8.
- ↑ Kishida I, Kawanishi C, Furuno T, Kato D, Ishigami T, Kosaka K (2004). "Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene". Mol. Psychiatry 9 (3): 293-8. DOI:10.1038/sj.mp.4001422. PMID 15094790. Research Blogging.
- ↑ Baker WL, White CM, Coleman CI (2008). "Effect of nonergot dopamine agonists on symptoms of restless legs syndrome". Ann Fam Med 6 (3): 253–62. DOI:10.1370/afm.845. PMID 18474889. Research Blogging.
- ↑ Online Mendelian Inheritance in Man, OMIM®. Johns Hopkins University, Baltimore, MD. MIM Number: 601696 . World Wide Web URL: http://omim.org/.